Abstract

BackgroundIn rheumatoid arthritis (RA), autoantibodies are a reflection of the underlying B cell autoimmunity and an important predictor of long-term outcome. Baseline seropositivity is a poor prognostic factor for sustained...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
P007 In ra, becoming seronegative over the 1st year of dmard treatment does not translate to better chances of drug-free remission in the long-term
Yp Goekoop-Ruiterman ... Gm Steup-Beekman
Annals of the Rheumatic Diseases | VOL. 77
Yp Goekoop-Ruiterman, et. al.Yp Goekoop-Ruiterman ... Gm Steup-Beekman
21 Feb 2018
AB0084 Breadth of baseline autoantibody profile and treatment response in rheumatoid arthritis patients
Rj Goekoop ... Twj Huizinga
Annals of the Rheumatic Diseases | VOL. 76
Rj Goekoop, et. al.Rj Goekoop ... Twj Huizinga
01 Jun 2017
POS0103 IN RHEUMATOID ARTHRITIS, THE ASSOCIATION BETWEEN ANTI-MODIFIED PROTEIN ANTIBODIES AND LONG-TERM OUTCOMES IS DOMINATED BY THE EFFECT OF ANTI-CITRULLINATED PROTEIN ANTIBODIES
R Knevel ... R Toes
-
R Knevel, et. al.R Knevel ... R Toes
23 May 2022
In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission
Tom W J Huizinga ... Yvonne P M Goekoop-Ruiterman
Annals of the Rheumatic Diseases | VOL. 77
Tom W J Huizinga, et. al.Tom W J Huizinga ... Yvonne P M Goekoop-Ruiterman
25 Jul 2018
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers